PGNY
Progyny, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$30.50
+4.95%Oct 26, 2026, 15:25 UTC
Progyny announced findings from a new clinical outcomes study showing that more than 70% of members in its Menopause and Midlife program experienced improvement in menopause symptoms.
Source:Oct 21, 2026, 14:43 UTC
Progyny announced that it will report financial results for the quarter ended September 30, 2026, after market close on November 4, 2026.
Source:Oct 8, 2026, 11:20 UTC
Progyny, Inc. shares rose 6.3% in the last trading session on above-average volume.
Source:Oct 7, 2026, 12:28 UTC
Progyny said commitments received and anticipated remaining decisions in its current annual selling season are expected to add 1.2 million covered lives through launches in the first half of 2027.
Source:Aug 15, 2026, 03:49 UTC
Progyny reported Q2 CY2026 revenue of $350.5 million and adjusted EPS of $0.55, beating analyst estimates, but the stock fell in reaction.
Source:Aug 11, 2026, 23:59 UTC
Progyny Inc's stock fell 4.6% to $26.55 on August 11, 2026.
Source:Aug 6, 2026, 21:55 UTC
Progyny reported Q2 2026 adjusted earnings of $0.55 per share on revenue of $350.51 million, beating analyst estimates of $0.34 and $348.69 million, respectively.